Kinnate Biopharma Inc.

NASDAQ:KNTE

2.65 (USD) • At close April 2, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

202320222021202020192018
Revenue 000000
Cost of Revenue 0.7990.6040.1230.08300
Gross Profit -0.799-0.604-0.123-0.08300
Gross Profit Ratio 000000
Reseach & Development Expenses 90.76788.1567.16629.2378.9555.675
General & Administrative Expenses 030.37122.9456.7643.0571.955
Selling & Marketing Expenses 000000
SG&A 27.44230.37122.9456.7643.0571.955
Other Expenses 02.250.348-0.00500
Operating Expenses 118.209118.52190.11136.00112.0127.63
Operating Income -119.008-118.521-90.111-36.001-12.012-7.63
Operating Income Ratio 000000
Total Other Income Expenses Net 6.3592.250.3480.240.0430
Income Before Tax -112.649-116.271-89.763-35.761-11.969-7.63
Income Before Tax Ratio 000000
Income Tax Expense 0-2.25-0.348-0.328-0.0430
Net Income -112.649-114.021-89.415-35.433-11.926-7.63
Net Income Ratio 000000
EPS -2.42-2.59-2.05-0.81-0.28-0.71
EPS Diluted -2.42-2.59-2.05-0.81-0.28-0.71
EBITDA -118.209-117.917-89.988-35.918-12.012-7.63
EBITDA Ratio 000000